Once-monthly minodronic acid filed for approval in Japan
This article was originally published in Scrip
Astellas and local partner Ono have filed for the Japanese approval of a once-monthly formulation of the oral bisphosphonate, minodronic acid hydrate, for the treatment of osteoporosis.
You may also be interested in...
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.